Retinoic Acid News and Research

RSS
Retinoic Acid is a nutrient that that body needs in small amounts to function and stay healthy. All-trans retinoic acid is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. A form of all-trans retinoic acid made in the laboratory is put on the skin to treat conditions such as acne and is taken by mouth to treat acute promyelocytic leukemia (a fast-growing cancer in which there are too many immature blood-forming cells in the blood and bone marrow). All-trans retinoic acid is being studied in the prevention and treatment of other types of cancer. Also called ATRA, retinoic acid, tretinoin, and vitamin A acid.
Researchers aim to design a better male contraceptive pill

Researchers aim to design a better male contraceptive pill

Genetic factors in puberty timing: an interview with Dr John Perry

Genetic factors in puberty timing: an interview with Dr John Perry

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Large doses of vitamin A reduce severity of gastrointestinal disease in mice

Large doses of vitamin A reduce severity of gastrointestinal disease in mice

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Lycera achieves milestone in Merck research collaboration

Lycera achieves milestone in Merck research collaboration

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec raises €4.8 million in second closing of Series A financing round

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

Researchers identify previously unknown effect of vitamin A in embryonic development

Researchers identify previously unknown effect of vitamin A in embryonic development

NR2F1 gene: A 'master regulator' of tumor cell growth

NR2F1 gene: A 'master regulator' of tumor cell growth

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Surgical membrane delivers healing action of vitamin A

Surgical membrane delivers healing action of vitamin A

UM researchers explain signaling systems that tissues use to communicate at the head-trunk region

UM researchers explain signaling systems that tissues use to communicate at the head-trunk region

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia initiates Phase 2 extension study of palovarotene in FOP patients